Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amira Pharmaceuticals and GlaxoSmithKline have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP or 5-lipoxygenase activating protein inhibitors for the treatment of respiratory and cardiovascular diseases.
Subscribe to our email newsletter
Under the terms of the agreement GlaxoSmithKline (GSK) will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira’s FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to $425 million in upfront and milestone payments.
In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.